DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery

Information source: Northwestern University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Brain and Central Nervous System Tumors

Intervention: arsenic trioxide (Drug); temozolomide (Drug); radiation therapy (Radiation)

Phase: Phase 1/Phase 2

Status: Active, not recruiting

Sponsored by: Northwestern University

Official(s) and/or principal investigator(s):
Jeffrey Raizer, MD, Principal Investigator, Affiliation: Northwestern University


RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving arsenic trioxide and temozolomide together with radiation therapy after surgery may kill any remaining tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of arsenic trioxide and temozolomide when given together with radiation therapy and to see how well they work in treating patients with malignant glioma that has been removed by surgery.

Clinical Details

Official title: A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination With Radiation Therapy for Patients With Malignant Gliomas

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Maximum tolerated dose of arsenic trioxide and temozolomide in combination with radiotherapy

Collect data on the toxicity of arsenic and temozolomide during radiation therapy

Assess serum biomarkers and correlate with tumor tissue

Secondary outcome:

Determine progression free survival at 6 and 12 months

Determine time to disease progression

To determine overall survival

To determine radiographic response to study regimen

To collect safety data during the radiation therapy phase

To evaluate a potential surrogate marker for outcomes

Detailed description: OBJECTIVES: Primary

- Determine the maximum tolerated dose (MTD) of arsenic trioxide and temozolomide when

combined with radiotherapy in patients with resected supratentorial malignant glioma. (Phase I)

- Determine the toxicity of this regimen in these patients. (Phase I)


- Determine the 6- and 12-month progression-free survival of patients treated with this

regimen once an MTD is reached. (Phase II)

- Determine the radiographic response for patients treated with the above regimen. (Phase


- Determine the safety of this regimen in these patients. (Phase II)

OUTLINE: This is a phase I, dose-escalation study of arsenic trioxide and temozolomide followed by a phase II study.

- Phase I: Patients undergo radiotherapy once daily 5 days a week and receive oral

temozolomide once daily for approximately 6½ weeks. Patients also receive arsenic trioxide IV over 1-4 hours once daily, 5 days a week in week 1 and then twice a week in weeks 2-7. Beginning within 3-5 weeks after completion of radiotherapy, patients receive oral temozolomide once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 1 year in the absence of disease progression and unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of arsenic trioxide and temozolomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 1 of 3 or 2 of 6 patients experience dose-limiting toxicity.

- Phase II: Patients undergo radiotherapy and receive arsenic trioxide and temozolomide

as in phase I at the MTD. Patients then receive temozolomide as in phase I for up to 1 year in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for 1 year. PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for the phase I portion of this study. A total of 25 patients will be accrued for the phase II portion of this study.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.



- Histologically confirmed supratentorial malignant glioma of 1 of the following types:

- Glioblastoma multiforme

- Gliosarcoma

- Anaplastic astrocytoma

- Anaplastic oligodendroglioma

- Anaplastic mixed gliomas

- Anaplastic gliomas not otherwise specified

- Has undergone surgical resection of tumor

- Patients with biopsy only are eligible

- Evaluable or measurable disease following resection of recurrent tumor is not

mandated for entry into the study

- No brain metastases


- Karnofsky performance status 60-100%

- Life expectancy > 3 months

- WBC > 3,000/mm^3

- Absolute neutrophil count > 2,000/mm^3

- Platelet count > 100,000/mm^3

- Hemoglobin > 10 g/dL (eligibility level for hemoglobin may be reached by transfusion)

- Creatinine ≤ 1. 5 mg/dL

- Bilirubin ≤ 2 mg/dL

- Transaminases ≤ 2 times the upper limit of normal

- Serum potassium* > 4. 0 mEq/dL

- Serum magnesium* > 1. 8 mg/dL NOTE: *If these serum electrolytes are below the

specified limits on the baseline laboratory tests, supplemental electrolytes should be administered to bring the serum concentrations to these levels before administering arsenic trioxide

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 3 months after

completion of study treatment

- No second-degree heart block

- QT interval ≤ 460 msec

- No other malignancy within the past 3 years except curatively treated carcinoma in

situ or basal cell carcinoma of the skin

- Patients who cannot undergo MRI are not eligible for this study

- No other serious concurrent infection or other medical illness that would jeopardize

the ability of the patient to receive the therapy in this protocol with reasonable safety PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- Patients must have recovered from the effects of surgery prior to the start of

treatment (10-14 days minimum) and be maintained on a stable corticosteroid regimen for 5 days

- Concurrent glucocorticoid therapy allowed at the smallest effective dose

- Patients must be on non-enzyme-inducing anti-convulsants to minimize any drug


- No prior radiation therapy, chemotherapy, immunotherapy, therapy with biologic agents

(including immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy), or hormonal therapy for their brain tumor

Locations and Contacts

Hematology-Oncology Associates of Illinois, Chicago, Illinois 60611-2998, United States

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois 60611-3013, United States

Edward Cancer Center, Naperville, Illinois 60540, United States

Additional Information

Starting date: May 2005
Last updated: August 4, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017